Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance
- PMID: 9773807
- DOI: 10.1097/00001813-199808000-00008
Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance
Abstract
Recent preclinical and clinical data indicate that the main mechanisms of 5-fluorouracil (5-FU) cytotoxicity depend on the mode of administration. To gather further insight into the major causes of acquired 5-FU resistance, drug-sensitive human gastric (M2), colon (HT29) and breast (MCF7) cancer cell lines were repeatedly exposed to a fixed concentration of 5-FU given either for 1 or 24 h. Although equieffective doses (IC50) of 5-FU were used, resistance to a 1 h exposure of 5-FU developed faster in all models than to a 24 h exposure. Cell lines with acquired resistance to a 1 h application of 5-FU were only partly cross-resistant to a 24 h exposure, whereas lines with resistance to protracted application of 5-FU displayed significant cross-resistance to the 1 h schedule. Resistance to methotrexate was only seen in cell lines with acquired resistance to 24 h of 5-FU. All 5-FU-resistant cell lines showed reduced incorporation of 5-FU into cellular RNA. Furthermore, elevations of thymidylate synthase were seen in all cell lines with resistance to 24 h of 5-FU but also in one cell line with resistance to a bolus schedule. No alterations in folylpolyglutamate synthase developed in the resistant cell lines. These data support the concept that the main mechanisms of 5-FU cytotoxicity depend on the mode of application. Incorporation of fluorouridine triphosphate into RNA appears to be the most important mechanism of action for 5-FU bolus schedules, whereas inhibition of thymidylate synthase becomes more important as the infusion time is prolonged. These data could have implications on the interaction of 5-FU given at different schedules with various other cytostatic agents.
Similar articles
-
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.J Natl Cancer Inst. 1993 Dec 1;85(23):1937-44. doi: 10.1093/jnci/85.23.1937. J Natl Cancer Inst. 1993. PMID: 8230285
-
Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.Br J Cancer. 2000 Dec;83(11):1510-5. doi: 10.1054/bjoc.2000.1456. Br J Cancer. 2000. PMID: 11076661 Free PMC article.
-
Cytotoxic effects and mechanisms of an alteration in the dose and duration of 5-fluorouracil.Anticancer Res. 2003 Jan-Feb;23(1A):447-52. Anticancer Res. 2003. PMID: 12680247
-
[Infusiontherapy with 5-fluorouracil ("infusional" 5-FU) in solid tumors].Med Klin (Munich). 2000 Jun;95 Suppl 1:3-8. Med Klin (Munich). 2000. PMID: 10941246 Review. German.
-
[Recent advance in chemotherapy for advanced colorectal cancer].Gan To Kagaku Ryoho. 1996 Apr;23(5):535-48. Gan To Kagaku Ryoho. 1996. PMID: 8678510 Review. Japanese.
Cited by
-
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.BMC Cancer. 2010 Sep 1;10:470. doi: 10.1186/1471-2407-10-470. BMC Cancer. 2010. PMID: 20809970 Free PMC article.
-
Methionine-dependence and combination chemotherapy on human gastric cancer cells in vitro.World J Gastroenterol. 2002 Apr;8(2):230-2. doi: 10.3748/wjg.v8.i2.230. World J Gastroenterol. 2002. PMID: 11925597 Free PMC article.
-
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.Br J Cancer. 2017 May 9;116(10):1271-1278. doi: 10.1038/bjc.2017.93. Epub 2017 Apr 11. Br J Cancer. 2017. PMID: 28399112 Free PMC article. Clinical Trial.
-
The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.Pharmacogenomics J. 2017 Jul;17(4):319-324. doi: 10.1038/tpj.2016.23. Epub 2016 Mar 22. Pharmacogenomics J. 2017. PMID: 27001120
-
Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.World J Gastroenterol. 2016 Jun 21;22(23):5332-41. doi: 10.3748/wjg.v22.i23.5332. World J Gastroenterol. 2016. PMID: 27340349 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical